The action will remove from use the very few flu shots that contain the contested preservative, elevating unproven fears it ...

The Swiss company, which markets Elevidys abroad, said it believes the benefit-risk balance to treatment remains positive in ...

The French biotech is developing a new drug approach in a disease market that’s projected to grow to $30 billion by 2030.

The startup is using elements of gene and cell therapy to create medicines that could be useful against an array of tough-to-treat solid tumors.